Clinical response to persistent, low-level β-glucuronidase expression in the murine model of mucopolysaccharidosis type VII

Journal of Inherited Metabolic Disease

Volumn 30, Issue 2, 2007, Pages 227-238

  Donsante, A ^a   Levy, B ^b   Vogler, C ^b   Sands, M S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; BETA GLUCURONIDASE; GLYCOSAMINOGLYCAN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; BONE DYSPLASIA; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; ELECTRORETINOGRAPHY; ENZYME ACTIVITY; ENZYME DEFICIENCY; EVOKED AUDITORY RESPONSE; HEARING IMPAIRMENT; HISTOPATHOLOGY; LIFESPAN; LIVER LEVEL; LYSOSOME STORAGE DISEASE; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NERVE CELL; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REPRODUCTION; RETINA DEGENERATION; VIRUS RECOMBINANT;

ALPHA-GALACTOSIDASE; ANIMALS; BONE DISEASES, DEVELOPMENTAL; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLUCURONIDASE; GLYCOSAMINOGLYCANS; HEARING; LIVER; LONGEVITY; LYSOSOMES; MICE; MUCOPOLYSACCHARIDOSIS VII; REPRODUCTION; RETINA; TISSUE DISTRIBUTION;

EID: 33947666020     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-007-0483-4     Document Type: Article

References (53)

1. Achord DT, Brot FE, Bell CE, Sly WS (1978) Human beta-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15 (1): 269-278.
2. Birkenmeier EH, Davisson MT, Beamer WG, et al (1989) Murine mucopolysaccharidosis type VII Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 83 (4): 1258-1266.
3. Birkenmeier EH, Barker JE, Vogler CA, et al (1991) Increased lifespan and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood 78: 3081-3092.
4. Bjornsson S (1993) Simultaneous preparation and quantitation of proteoglycans by precipitation with alcian blue. Anal Biochem 210 (2): 282-291.
5. Daly TM, Vogler C, Levy B, Haskins ME, Sands MS (1999a) Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci USA 96 (5): 2296-2300.
6. Daly TM, Okuyama T, Vogler C, Haskins ME, Muzyczka N, Sands MS (1999b) Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum Gene Ther 10 (1): 85-94.
7. Daly TM, Ohlemiller KK, Roberts MS, Vogler CA, Sands MS (2001) Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther 8 (17): 1291-1298.
8. Ellinwood NM, Vite CH, Haskins ME (2004) Gene therapy for lysosomal storage diseases: The lessons and promise of animal models. J Gene Med 4: 481-506.
9. Fraites TJ Jr, et al (2002) Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 5 (5 Pt 1): 571-578. 571-578.
10. Gao C, Sands MS, Haskins ME, Ponder KP (2000) Delivery of a retroviral vector expressing human β-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. Mol Ther 2 (2): 233-244.
11. Greaton CJ, Lane KB, Shepherd VL, McLaughlin BJ (2003) Transcription of a single mannose receptor gene by macrophage and retinal pigment epithelium. Ophthalmic Res 35 (1): 42-47.
12. Grimm D, Kern A, Rittner K, Kleinschmidt JA (1998) Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 9 (18): 2745-2760.
13. Hafenrichter DG, Wu X, Rettinger SD, Kennedy SC, Flye MW, Ponder KP (1994) Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood 84 (10): 3394-3404.
14. Hartung SD, Frandsen JL, Pan D, et al (2004) Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-l-iduronidase gene. Mol Ther 9 (6): 866-875.
15. Jin HK, Schuchman EH (2003) Ex vivo gene therapy using bone marrow-derived cells: Combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease. Mol Ther 8 (6): 876-885.
16. Kobayashi H, Carbonaro D, Pepper K, et al (2005) Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 11 (5): 776-789.
17. Kornfeld S (1992) Structure and function of the mannose 6-phosphate/ insulinlike growth factor II receptors. Annu Rev Biochem 61: 307-330.
18. Kosuga M, Takahashi S, Sasaki K, et al (2000) Phenotype correction in murine mucopolysaccharidosis type VII by transplantation of human amniotic epithelial cells after adenovirus-mediated gene transfer. Cell Transplant 9 (5): 687-692.
19. Lazarus HS, Sly WS, Kyle JW, Hageman GS (1993) Photoreceptor degeneration and altered distribution of interphotoreceptor matrix proteoglycans in the mucopolysaccharidosis VII mouse. Exp Eye Res 56 (5): 531-541.
20. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281: 249-254.
21. Monroy MA, Ross FP, Teitelbaum SL, Sands MS (2002) Abnormal osteoclast morphology and bone remodeling in a murine model of lysosomal storage disease. Bone 30: 352-359.
22. Moullier P, Bohl D, Heard JM, Danos O (1993) Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat Genet 4 (2): 154-159.
23. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA (2001) Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75 (15): 6969-6976.
24. Neufeld EF, Fratantoni JE (1970) Inborn errors of mucopolysaccharide metabolism. Science 169: 141-146.
25. Neufeld EF, Muenzer J (2001) The mucopolysaccharisdoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3421-3452.
26. O'Connor LH, Erway LC, Vogler CA, et al (1998) Enzyme replacement therapy for murine mucopolysaccharidosis type VII: Improvements in behavior and auditory function. J Clin Invest 101: 1394-1400. 1394-1400.
27. Ohlemiller KK, Vogler CA, Roberts M, Galvin N, Sands MS (2000) Retinal function is improved in a murine model of lysosomal storage disease following bone marrow transplantation. Exp Eye Res 71: 469-481.
28. Ohlemiller KK, Hennig AK, Lett JM, Heidbreder AF, Sands MS (2002) Inner ear pathology in the mucopolysaccharidosis VII mouse. Hear Res 169: 69-84.
29. Park J, Murray GJ, Limaye A, et al (2003) Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci USA 100 (6): 3450-3454.
30. Ponder KP, Melniczek JR, Xu L, et al (2002) Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA 99 (20): 13102-13107.
31. Sands MS, Barker JE (1999) Percutaneous intravenous injection in neonatal mice. Lab Anim Sci 49 (3): 328-330.
32. Sands MS, Birkenmeier EH (1993) A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII. Proc Natl Acad Sci USA 90 (14): 6567-6571.
33. Sands MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13: 839-849.
34. Sands MS, Barker JE, Vogler C, et al (1993) Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest 68 (6): 676-686.
35. Sands MS, Vogler C, Kyle JW, et al (1994) Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 93: 2324-2331.
36. Sands MS, Erway LC, Vogler C, Sly WS, Birkenmeier EH (1995) Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII. Blood 86 (5): 2033-2040.
37. Sands MS, Vogler CA, Ohlemiller KK, et al (2001) Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem 276 (46): 43160-43165.
38. Schuldt AJ, Hampton TJ, Chu V, et al (2004) Electrocardiographic and other cardiac anomalies in beta-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation. Proc Natl Acad Sci USA 101 (2): 603-608.
39. Sferra TJ, Backstrom K, Wang C, Rennard R, Miller M, Hu Y (2004) Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol Ther 10: 478-491.
40. Sly WS, Quinton BA, McAlister WH, Rimoin DL (1973) Beta-glucuronidase deficiency: Report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr 82 (2): 249-257.
41. Soper BW, Pung AW, Vogler CA, Grubb JH, Sly WS, Barker JE (1999) Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses. Pediatr Res 45 (2): 180-186. 180-186.
42. Soper BW, Lessard MD, Vogler CA, et al (2001) Nonablative neonatal marrow transplantation attenuates functional and physical defects of β-glucuronidase deficiency. Blood 97 (5): 1498-1504.
43. Vervoort R, Gitzelmann R, Bosshard N, Maire I, Liebaers I, Lissens W (1998) Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote. Hum Genet 102 (1): 69-78.
44. Vogler C, Sands MS, Levy B, Galvin N, Birkenmeier EH, Sly WS (1996) Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: Impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res 39 (6): 1050-1054.
45. Vogler C, Levy B, Galvin NJ, et al (1999) Enzyme replacement in murine mucopolysaccharidosis type VII: Neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res 45 (6): 838-844.
46. Vogler C, Levy B, Grubb JH, et al (2005a) Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 102 (41): 14777-14782.
47. Vogler C, Levy B, Galvin N, Lessard M, Soper B, Barker J (2005b) Early onset of lysosomal storage disease in a murine model of mucopolysaccharidosis type VII: Undegraded substrate accumulates in many tissues in the fetus and very young MPS VII mouse. Pediatr Dev Pathol 8 (4): 453-462.
48. Wolfe JH, Sands MS, Barker JE, et al (1992) Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 360 (6406): 749-753.
49. Wolfe JH, Sands MS, Harel N, et al (2000) Gene transfer of low levels of beta-glucuronidase corrects hepatic lysosomal storage in a large animal model of mucopolysaccharidosis VII. Mol Ther 2 (6): 552-561.
50. Woloszynek JC, Roberts M, Coleman T, et al (2004) Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII. Biochem J 379 (Pt 2): 461-469.
51. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM (1998) Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 72 (12): 10222-10226.
52. Xu F, Ding E, Migone F, et al (2005) Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. J Gene Med 7 (2): 171-178.
53. Zolotukhin S, Byrne BJ, Mason E, et al (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6 (6): 973-985.